Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biom...

Descripción completa

Detalles Bibliográficos
Autores principales: Spratlin, Jennifer L., Mulder, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189759/
https://www.ncbi.nlm.nih.gov/pubmed/22016635
http://dx.doi.org/10.3390/ijms12095895
Descripción
Sumario:The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.

Ejemplares similares